Association between a sepsis alert system and emergency department revisits: evidence from patients on haemodialysis
Published
November 8, 2025
Paper ID
PAP-000091
Status
Published
DOI
10.65712/tmj.test000349
Advance Services
Abstract
Background: The cost of emergency department revisits to health systems is substantial. Methods: We conducted a retrospective cohort study across 13 centres between 2017 and 2021. Results: Serious adverse events were rare and similar between groups. 2342 participants were included (median age 72 years). Conclusion: Future work should test a sepsis alert system in a pragmatic multicentre trial.
Introduction
The cost of emergency department revisits to health systems is substantial. Guidelines make only a weak recommendation on a sepsis alert system.
Earlier studies of a sepsis alert system were small or single-centre. Guidelines make only a weak recommendation on a sepsis alert system. Practice around a sepsis alert system varies widely between centres.
The cost of emergency department revisits to health systems is substantial. Practice around a sepsis alert system varies widely between centres.
Practice around a sepsis alert system varies widely between centres. Earlier studies of a sepsis alert system were small or single-centre.
Discussion
Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols.
These findings suggest that a sepsis alert system is associated with better emergency department revisits in patients on haemodialysis. Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded.
Future work should test a sepsis alert system in a pragmatic multicentre trial. Residual confounding cannot be excluded. These findings suggest that a sepsis alert system is associated with better emergency department revisits in patients on haemodialysis.
Conclusions
A sepsis alert system should be considered for patients on haemodialysis to improve emergency department revisits.
References
1. Yilmaz F, Nakamura X, et al. Pharmacist-led medication review and medication adherence. Lancet. 2013;236(1):411-974.
2. Larsen E, Tanaka E, et al. Pharmacist-led medication review and medication adherence. Pediatrics. 2010;18(5):384-1499.
3. Volkov A, Costa C, et al. Early enteral nutrition and health-related quality of life. Pediatrics. 2020;134(3):661-1507.
4. Ibrahim K, Herrera L, et al. An antibiotic stewardship programme and health-related quality of life. Pediatrics. 2025;145(9):739-1315.
5. Herrera H, Patel V, et al. Tranexamic acid and acute kidney injury. Lancet. 2022;319(11):744-1418.
6. Kim E, Osei K, et al. Home-based cardiac rehabilitation and surgical site infection. JAMA. 2010;368(8):477-1046.
Appendices
The statistical analysis plan is in the online supplement.
Materials and Methods
The primary outcome was emergency department revisits, assessed blind to allocation.
We conducted a retrospective cohort study across 13 centres between 2015 and 2025. We conducted a retrospective cohort study across 4 centres between 2015 and 2025. The primary outcome was emergency department revisits, assessed blind to allocation.
Eligible participants were patients on haemodialysis. Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity.
Results
emergency department revisits occurred in 20% of the intervention group versus 16% of controls. The adjusted odds ratio was 0.69 (95% CI 0.34 to 0.63).
Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups. 4201 participants were included (median age 68 years).
4519 participants were included (median age 71 years). The adjusted odds ratio was 0.89 (95% CI 0.43 to 0.98).
| Group | n | Events |
|---|---|---|
| Age < 65 | 284 | 85 |
| Female | 199 | 65 |
| Age < 65 | 511 | 27 |
| Female | 74 | 76 |
| Centre A | 305 | 55 |
| Intervention | 388 | 59 |
Values are n (%) unless stated otherwise.

Shown for patients on haemodialysis; error bars are 95% confidence intervals.

Shown for patients on haemodialysis; error bars are 95% confidence intervals.
Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups. 379 participants were included (median age 73 years).